XML 71 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock Incentive Plans (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss, including $1.5 million recognized as stock-based compensation expense upon the achievement of a technical milestone by Ginkgo Bioworks Holdings, Inc., or Ginkgo, during the year ended December 31, 2023 as described in Note 16, was as follows (in thousands):
 Year Ended December 31,
 20242023
Research and development$3,217 $12,985 
General and administrative3,365 12,793 
Total stock-based compensation expense$6,582 $25,778 
Schedule of Weighted Average Assumptions Used
The fair value of the stock options assumed in connection with the Merger was calculated using a Black-Scholes option pricing model based on the following weighted-average assumptions:
Common StockSeries A Preferred Stock
Risk-free interest rate4.83 %4.92 %
Dividend yield— — 
Expected term3.593.29
Expected volatility83.77 %83.87 %
Weighted-average fair value of common stock or Series A Preferred Stock, as applicable$12.00 $403.47 
The estimated grant date fair values of stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model based on the following weighted-average assumptions:
Year Ended December 31,
 20242023
Risk-free interest rate4.02 %3.95 %
Dividend yield— — 
Expected term6.215.94
Expected volatility95.21 %94.64 %
Weighted-average fair value of common stock$19.63 $34.54 
Schedule of Stock Option Activity
The following table summarizes the stock option activity under the 2016 Plan, the 2018 Inducement Incentive Award Plan, and the Old Cartesian Plan for options for common stock:
   Weighted-average 
 Number ofremainingAggregate
 common stockWeighted-averagecontractual termintrinsic value
 optionsexercise price ($)(in years)(in thousands)
Outstanding at December 31, 2023776,865 $2.97 6.50$13,760 
Granted1,000,092 $19.63   
Converted from options for Series A Preferred Stock470,403 $2.40 
Exercised(458,544)$2.57   
Forfeited(82,781)$17.28   
Outstanding at December 31, 20241,706,035 $11.99 7.59$12,025 
Vested at December 31, 2024656,258 $3.22 5.36$9,674 
Vested and expected to vest at December 31, 20241,564,044 $11.31 7.44$11,961 
The following table summarizes the stock option activity under the Old Cartesian Plan for options for Series A Preferred Stock:
 Number of Weighted-average 
 Series A remainingAggregate
 Preferred StockWeighted-averagecontractual termintrinsic value
 optionsexercise price ($)(in years)(in thousands)
Outstanding at December 31, 202314,112.299 $79.94 5.91$8,601 
Converted to options for common stock(14,112.299)$79.94   
Outstanding at December 31, 2024— $— 
Schedule of Restricted Stock Units Activity
The following table summarizes the Company’s restricted stock units under the 2016 Plan and the Old Cartesian Plan:
 Number of sharesWeighted average
grant date
fair value ($)
Unvested at December 31, 2023
— $— 
Granted477,037 19.86 
Forfeited(32,799)19.80 
Unvested at December 31, 2024
444,238 $19.86